Suppr超能文献

在美国替代活体钩端螺旋体病疫苗效力检测。

Replacement of in vivo leptospirosis vaccine potency testing in the United States.

机构信息

PETA Science Consortium International e.V, Friolzheimer Str. 3, 70499, Stuttgart, Germany.

PETA Science Consortium International e.V, Friolzheimer Str. 3, 70499, Stuttgart, Germany.

出版信息

Biologicals. 2022 Jul;78:36-44. doi: 10.1016/j.biologicals.2022.05.001. Epub 2022 Jun 24.

Abstract

The U.S. Department of Agriculture (USDA) regulates the potency testing of leptospirosis vaccines, which are administered to animals to protect against infection by Leptospira bacteria. Despite the long-term availability of in vitro test methods for assessing batch potency, the use of hamsters in lethal in vivo batch potency testing persists to varying degrees across leptospirosis vaccine manufacturers. For all manufacturers of these products, data collected from public USDA records show an estimated 40% decline in the annual use of hamsters from 2014 to 2020, with an estimated 55% decrease in the number of hamsters expected to have been used in leptospirosis vaccine potency tests (i.e., those in USDA Category E). An estimated 49,000 hamsters were used in 2020, with about 15,000 hamsters in Category E specifically. Based on this assessment, additional efforts are needed to fully implement in vitro batch potency testing as a replacement for the in vivo batch potency test. We propose steps that can be taken collaboratively by the USDA Center for Veterinary Biologics (CVB), manufacturers of leptospirosis vaccines, government agencies, and non-governmental organizations to accelerate broader use of the in vitro approach.

摘要

美国农业部(USDA)负责监管钩端螺旋体病疫苗的效力测试,这些疫苗被用于动物,以预防钩端螺旋体细菌感染。尽管长期以来一直有体外测试方法可用于评估批次效力,但在钩端螺旋体病疫苗制造商中,仓鼠在致死性体内批次效力测试中的使用程度仍存在差异。对于这些产品的所有制造商,从 USDA 公开记录中收集的数据显示,2014 年至 2020 年,仓鼠的年使用量估计下降了 40%,预计在钩端螺旋体病疫苗效力测试(即 USDA 类别 E)中使用的仓鼠数量减少了 55%。2020 年估计使用了 49,000 只仓鼠,其中约 15,000 只仓鼠在类别 E 中。基于这一评估,需要进一步努力,将体外批次效力测试全面实施为体内批次效力测试的替代方法。我们提出了 USDA 兽医生物制品中心(CVB)、钩端螺旋体病疫苗制造商、政府机构和非政府组织可以共同采取的步骤,以加快更广泛地采用体外方法。

相似文献

1
Replacement of in vivo leptospirosis vaccine potency testing in the United States.
Biologicals. 2022 Jul;78:36-44. doi: 10.1016/j.biologicals.2022.05.001. Epub 2022 Jun 24.
2
USDA regulatory guidelines and practices for veterinary Leptospira vaccine potency testing.
Biologicals. 2013 Sep;41(5):298-302. doi: 10.1016/j.biologicals.2013.06.005. Epub 2013 Jul 6.
4
Opportunities and strategies to further reduce animal use for Leptospira vaccine potency testing.
Biologicals. 2013 Sep;41(5):332-7. doi: 10.1016/j.biologicals.2013.06.006. Epub 2013 Jul 24.
7
European regulatory framework and practices for veterinary Leptospira vaccine potency testing.
Biologicals. 2013 Sep;41(5):303-4. doi: 10.1016/j.biologicals.2013.06.014. Epub 2013 Jul 22.
8
10
Product-specific validation of a serological potency test for release of Leptospira vaccines in the European Union.
Biologicals. 2013 Sep;41(5):330-1. doi: 10.1016/j.biologicals.2013.06.004. Epub 2013 Jul 10.

本文引用的文献

1
.
Procedia Vaccinol. 2011;5:60-83. doi: 10.1016/j.provac.2011.10.005. Epub 2011 Dec 23.
2
Increasing the use of animal-free recombinant antibodies.
ALTEX. 2020;37(2):309-311. doi: 10.14573/altex.2001071. Epub 2020 Jan 8.
3
Modern affinity reagents: Recombinant antibodies and aptamers.
Biotechnol Adv. 2015 Dec;33(8):1787-98. doi: 10.1016/j.biotechadv.2015.10.004. Epub 2015 Oct 19.
4
Reproducibility: Standardize antibodies used in research.
Nature. 2015 Feb 5;518(7537):27-9. doi: 10.1038/518027a.
5
Leptospirosis in humans.
Curr Top Microbiol Immunol. 2015;387:65-97. doi: 10.1007/978-3-662-45059-8_5.
6
Leptospirosis in cattle: a challenging scenario for the understanding of the epidemiology.
Transbound Emerg Dis. 2014 Aug;61 Suppl 1:63-8. doi: 10.1111/tbed.12233.
8
10
Leptospirosis: public health perspectives.
Biologicals. 2013 Sep;41(5):295-7. doi: 10.1016/j.biologicals.2013.06.010. Epub 2013 Jul 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验